

CITATION REPORT

List of articles citing

Urine markers for bladder cancer surveillance: a systematic review

DOI: 10.1016/j.eururo.2005.03.014
European Urology, 2005, 47, 736-48.

Source: <https://exaly.com/paper-pdf/38256038/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 410 | Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. <i>European Urology</i> , 2005 , 48, 951-6; discussion 956 | 10.2 | 38 |
| 409 | Recent advances in the treatment of bladder cancer. 2005 , 5, 1023-30 | | 1 |
| 408 | New Insights in Telomerase and Telomeric Proteins and Their Clinical Application to Urological Cancers. 2005 , 3, 189-199 | | |
| 407 | Value of the innovated technique agarose cell block in improving the sensitivity of urine cytology in cases of bladder carcinoma. 2006 , 30, 379-85 | | 10 |
| 406 | Discovery of urinary biomarkers. 2006 , 5, 1760-71 | | 302 |
| 405 | Urinary bladder tumor markers. 2006 , 24, 528-37 | | 39 |
| 404 | Bibliography. Current world literature. Bladder cancer. 2006 , 16, 386-9 | | |
| 403 | Bladder cancer. 2006 , 18, 277-83 | | 11 |
| 402 | Urinary markers in the detection of bladder cancer: what's new?. 2006 , 16, 350-5 | | 18 |
| 401 | Urine telomerase activity for the diagnosis of bladder cancer. 2006 , 3, 192-193 | | |
| 400 | Aneuploidy in bladder cancers: the utility of fluorescent in situ hybridization in clinical practice. 2006 , 98, 33-7 | | 11 |
| 399 | Early bladder cancer: concept, diagnosis, and management. 2006 , 11, 28-37 | | 32 |
| 398 | Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. 2006 , 24, 499-508 | | 16 |
| 397 | [Standards and perspectives in diagnosis and therapy of bladder carcinoma]. 2006 , 45 Suppl 4, 90-6 | | 0 |
| 396 | [Urine cytology and urine markers. Significance for clinical practice]. 2006 , 45, W1441-7; quiz W1448 | | 0 |
| 395 | Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay. <i>European Urology</i> , 2006 , 49, 196 | 10.2 | |
| 394 | Current practice in the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey. <i>European Urology</i> , 2006 , 49, 478-84 | 10.2 | 20 |

| | | | |
|-----|--|------|-----|
| 393 | Quantitative cytology on bladder wash versus voided urine: a comparison of results. <i>European Urology</i> , 2006 , 49, 1044-9; discussion 1049-50 | 10.2 | 5 |
| 392 | Partially degraded RNA from bladder washing is a suitable sample for studying gene expression profiles in bladder cancer. <i>European Urology</i> , 2006 , 50, 1347-55; discussion 1355-6 | 10.2 | 18 |
| 391 | Urinary biomarker profiling in transitional cell carcinoma. 2006 , 119, 2642-50 | | 80 |
| 390 | Can a point-of-care urine protein assay monitor bladder cancer recurrence?. 2006 , 3, 482-3 | | |
| 389 | Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. 2006 , 12, 2109-16 | | 155 |
| 388 | Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. 2006 , 12, 4851-8 | | 365 |
| 387 | Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer. 2006 , 6, 1301-11 | | 8 |
| 386 | Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. 2006 , 24, 5528-35 | | 62 |
| 385 | Fluorescence in situ hybridization: a multitarget approach in diagnosis and management of urothelial cancer. 2007 , 7, 11-9 | | 15 |
| 384 | Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience. 2007 , 45, 862-6 | | 32 |
| 383 | Bladder cancer. 2007 , 19, 241-7 | | 14 |
| 382 | Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. 2007 , 70, 449-53 | | 32 |
| 381 | Fluorescence in situ hybridization for detecting upper urinary tract tumors--a preliminary report. 2007 , 70, 753-7 | | 44 |
| 380 | Potential of urinary biomarkers in early bladder cancer diagnosis. 2007 , 7, 1105-15 | | 21 |
| 379 | [Bladder cancer in neurological patients: analysis of a single-centre series]. 2007 , 17, 1333-6 | | 11 |
| 378 | Diagnostic potential for urinary proteomics. 2007 , 8, 237-55 | | 55 |
| 377 | [Value of urinary markers in the diagnosis and follow-up of urothelial bladder tumours]. 2007 , 17, 23-34 | | 5 |
| 376 | Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. 2007 , 177, 1277-82; discussion 1282 | | 54 |

| | | | |
|-----|--|------|-----|
| 375 | [Influence of the delay in urinary NMP22 preanalytical processing]. 2007 , 31, 746-51 | | |
| 374 | Urine proteomics: the present and future of measuring urinary protein components in disease. 2007 , 177, 361-8 | | 156 |
| 373 | Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. 2007 , 121, 329-38 | | 35 |
| 372 | Ex vivo fluorescence imaging of normal and malignant urothelial cells to enhance early diagnosis. 2007 , 83, 1157-66 | | 7 |
| 371 | Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments. 2007 , 100, 11-6 | | 48 |
| 370 | Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. 2008 , 101, 26-9 | | 29 |
| 369 | Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. 2007 , 173, 131-5 | | 25 |
| 368 | Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. <i>European Urology</i> , 2007 , 51, 403-7; discussion 407-8 | 10.2 | 37 |
| 367 | Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. <i>European Urology</i> , 2007 , 51, 409-15; discussion 415 | 10.2 | 56 |
| 366 | UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. <i>European Urology</i> , 2007 , 51, 1275-80; discussion 1280 | 10.2 | 86 |
| 365 | Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. <i>European Urology</i> , 2007 , 51, 1267-74 | 10.2 | 30 |
| 364 | Should we abandon the FISH test?. <i>European Urology</i> , 2007 , 51, 1469-71 | 10.2 | 16 |
| 363 | Editorial comment on: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. <i>European Urology</i> , 2007 , 52, 1396-7 | 10.2 | 1 |
| 362 | Advances in the management of superficial bladder cancer. 2007 , 34, 85-97 | | 33 |
| 361 | Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. 2007 , 25, 581-93 | | 97 |
| 360 | [Comparison of perioperative methylene blue-stained and permanent Papanicolaou-stained urine cytology to detect patients with high-grade urothelial cancer or the urinary bladder. Part 1]. 2007 , 46, 1145-7 | | 0 |
| 359 | Variation of metabolites in normal human urine. 2007 , 3, 439-451 | | 128 |
| 358 | Epidemiologie, Diagnose und urinbasierte Untersuchungsverfahren beim Harnblasenkarzinom. 2007 , 13, 1067-1079 | | 1 |

| | | | |
|-----|--|------|-----|
| 357 | Defining the role of NMP22 in bladder cancer surveillance. 2008 , 26, 51-8 | | 27 |
| 356 | Apport de la cytologie urinaire (mthodologie, intffiet limites). 2008 , 2008, 25-36 | | |
| 355 | Considerations on the use of diagnostic markers in management of patients with bladder cancer. 2008 , 26, 39-44 | | 17 |
| 354 | PatientsSperceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. 2008 , 101, 1106-10 | | 81 |
| 353 | A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. 2008 , 101, 1448-53 | | 44 |
| 352 | Should molecular technology replace urine cytology?. 2008 , 102, 1361 | | 2 |
| 351 | Genomics: a preview of genomic medicine. 2008 , 102, 1221-7 | | 8 |
| 350 | The past, present and future of cystoscopy: the fusion of cystoscopy and novel imaging technology. 2008 , 102, 1228-33 | | 40 |
| 349 | Molecular biomarkers in urothelial bladder cancer. 2008 , 99, 646-52 | | 100 |
| 348 | Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University. 2008 , 19, 369-74 | | 6 |
| 347 | Urinary markers in bladder cancer. <i>European Urology</i> , 2008 , 53, 909-16 | 10.2 | 124 |
| 346 | Considerations on the use of urine markers for bladder cancer. <i>European Urology</i> , 2008 , 53, 880-1 | 10.2 | 5 |
| 345 | Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. 2008 , 7, 2088-96 | | 156 |
| 344 | Economic impact of tumor markers in bladder cancer surveillance. 2008 , 71, 131-5 | | 46 |
| 343 | Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. 2008 , 71, 718-22 | | 47 |
| 342 | Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma. 2008 , 72, 1159-63 | | 26 |
| 341 | Biological markers in the diagnosis of recurrent bladder cancer: an overview. 2008 , 8, 63-72 | | 8 |
| 340 | Diagnosis of Non-Muscle Invasive Bladder Cancer. 2008 , 7, 627-636 | | 1 |

| | | |
|-----|---|----------|
| 339 | Gene signatures for risk-adapted treatment of bladder cancer. 2008 , 166-74 | 2 |
| 338 | Detection of tumours of the urinary tract in voided urine. 2008 , 147-53 | 17 |
| 337 | Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. 2008 , 191-212 | 6 |
| 336 | Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. 2008 , 14, 742-9 | 61 |
| 335 | Contemporary diagnosis of bladder cancer. 2008 , 2, 713-20 | 1 |
| 334 | The detection of genetic markers of bladder cancer in urine and serum. 2008 , 18, 499-503 | 13 |
| 333 | Bladder cancer. 2008 , 20, 307-14 | 49 |
| 332 | Bladder Tumor Markers: A Review of the Literature. 2008 , 23, 249-261 | 5 |
| 331 | Clinical Utility of Fluorescence in Situ Hybridization for Voided Urine for the Diagnosis and Surveillance of Bladder Cancer. 2008 , 49, 307 | 1 |
| 330 | [Urinary bladder cancer]. 2008 , 149, 613-5 | |
| 329 | Combinations of urine-based tumour markers in bladder cancer surveillance. 2009 , 43, 461-6 | 43 |
| 328 | Urinary proteomic profiling for diagnostic bladder cancer biomarkers. 2009 , 6, 507-14 | 21 |
| 327 | UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. 2009 , 101, 98-105 | 86 |
| 326 | Human bladder cancer diagnosis using Multiphoton microscopy. 2009 , 7161, | 28 |
| 325 | Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. 2009 , 18, 1798-806 | 30 |
| 324 | Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer. 2009 , 9, 149 | 15 |
| 323 | Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). <i>European Urology</i> , 2009 , 55, 659-67 | 10.2 65 |
| 322 | Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. <i>European Urology</i> , 2009 , 56, 430-42 | 10.2 466 |

| | | |
|-----|--|-----|
| 321 | Immunoscreening of urinary bladder cancer cDNA library and identification of potential tumor antigen. 2009 , 27, 107-12 | 10 |
| 320 | The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. 2009 , 218, 104-12 | 40 |
| 319 | Diagnosis of urothelial carcinoma from urine. 2009 , 22 Suppl 2, S53-9 | 124 |
| 318 | Epigenetic markers as promising prognosticators for bladder cancer. 2009 , 16, 17-22 | 52 |
| 317 | Bladder cancer biomarkers and their role in surveillance and screening. 2009 , 16, 23-30 | 47 |
| 316 | Molecular markers for detection, surveillance and prognostication of bladder cancer. 2009 , 16, 234-43 | 42 |
| 315 | Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. 2009 , 104, 896-901 | 43 |
| 314 | Amino Acid Profile Determination in the Urine of Bladder Cancer Patients by CE-MS with On-Line pH-Mediated Stacking and Pattern Recognition. 2009 , 70, 1479-1484 | 20 |
| 313 | Urine-based assays for the detection of bladder cancer. 2009 , 3, 265 | 31 |
| 312 | Cytology and Urinary Markers for the Diagnosis of Bladder Cancer. 2009 , 8, 536-541 | 31 |
| 311 | Recurrence, Progression, and Follow-Up in NonMuscle-Invasive Bladder Cancer. 2009 , 8, 556-562 | 38 |
| 310 | Bladder cancer. 2009 , 374, 239-49 | 817 |
| 309 | DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. 2009 , 182, 741-8 | 55 |
| 308 | Current trends in the management of bladder cancer. 2009 , 36, 413-21; quiz 422-3 | 4 |
| 307 | Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers?. 2010 , 20, 388-92 | 9 |
| 306 | Bladder cancer: a review of non-muscle invasive disease. 2010 , 17, 256-68 | 71 |
| 305 | [Molecular markers in the diagnostics and therapy of urothelial cancer]. 2010 , 49, 1415-24 | 2 |
| 304 | Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. 2010 , 10, 646 | 48 |

| | | | |
|-----|--|------|-----|
| 303 | Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. <i>European Urology</i> , 2010 , 58, 96-104 | 10.2 | 120 |
| 302 | In-depth investigation of the molecular pathogenesis of bladder cancer in a unique 26-year old patient with extensive multifocal disease: a case report. 2010 , 10, 5 | | 5 |
| 301 | Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. 2010 , 101, 250-8 | | 72 |
| 300 | Biomarkers in bladder cancer. 2010 , 57, 1-13 | | 58 |
| 299 | miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. 2010 , 102, 883-91 | | 274 |
| 298 | Influence of clinical information on the interpretation of urinary cytology in bladder cancer: how suggestible is a cytologist?. 2010 , 106, 1165-8 | | 5 |
| 297 | The clinical significance of urine cytology after a radical cystectomy for urothelial cancer. 2010 , 17, 527-32 | | 23 |
| 296 | Tumor markers for bladder cancer: outlook for routine use1. 2010 , 34, - | | |
| 295 | Tumormarker beim Blasentumor: Aussichten ff den klinischen Alltag / Tumor markers for bladder cancer: outlook for routine use. 2010 , 34, 77-86 | | |
| 294 | Urologic Issues for the Nephrologist. 2010 , 716-725 | | |
| 293 | Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. 2010 , 16, 3011-8 | | 89 |
| 292 | Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. 2010 , 16, 2624-33 | | 63 |
| 291 | Reply by Authors. 2010 , 183, 827-828 | | |
| 290 | Developments in intravesical therapy for non-muscle-invasive bladder cancer. 2010 , 10, 1903-16 | | 7 |
| 289 | Evaluation of upper urinary tract tumors by FISH in Chinese patients. 2010 , 203, 238-46 | | 8 |
| 288 | Transitional cell carcinoma of the bladder in children and adolescents: six-case series and review of the literature. 2010 , 6, 481-5 | | 49 |
| 287 | UPK3A: a promising novel urinary marker for the detection of bladder cancer. 2010 , 76, 514.e6-11 | | 13 |
| 286 | Urinary cytology in era of fluorescence endoscopy: redefining the role of an established method with a new reference standard. 2010 , 76, 677-80 | | 12 |

| | | |
|-----|---|-----|
| 285 | Bladder cancer: novel molecular characteristics, diagnostic, and therapeutic implications. 2010 , 28, 91-6 | 11 |
| 284 | Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). 2010 , 28, 686-90 | 19 |
| 283 | The origins of urothelial carcinoma. 2010 , 10, 865-80 | 60 |
| 282 | Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. 2010 , 184, 879-82 | 40 |
| 281 | A Prospective Comparison of the NMP22 Bladderchek [®] Assay and Voided Urine Cytology in the Detection of Bladder Transitional Cell Carcinoma: Is it Time up for Urine Cytology?. 2011 , 4, 113-118 | 1 |
| 280 | Contemporary management of low-risk bladder cancer. 2011 , 8, 42-9 | 21 |
| 279 | Tumors of the Urinary System. 2011 , 434-464 | 1 |
| 278 | Evidence of abnormal tyrosine phosphorylated proteins in the urine of patients with bladder cancer: the road toward a new diagnostic tool?. 2011 , 185, 1922-9 | 13 |
| 277 | Bladder cancer: translating molecular genetic insights into clinical practice. 2011 , 42, 455-81 | 149 |
| 276 | Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study. 2011 , 77, 154-9 | 24 |
| 275 | Utility of a modality combining FISH and cytology in upper tract urothelial carcinoma detection in voided urine samples of Chinese patients. 2011 , 77, 636-41 | 22 |
| 274 | Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay. 2011 , 186, 707-12 | 32 |
| 273 | The Use of Bladder Tumor Markers in the Clinical Practice. 2011 , 5, 113-120 | 1 |
| 272 | Bladder Cancer. 395-416 | |
| 271 | Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma. 2011 , 107, 1833-8 | 9 |
| 270 | Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. 2011 , 108, 1119-23 | 51 |
| 269 | Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer. 2011 , 18, 439-43 | 4 |
| 268 | MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. 2011 , 102, 522-9 | 164 |

| | | | |
|-----|--|------|-----|
| 267 | Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. <i>European Urology</i> , 2011 , 59, 113-9 | 10.2 | 48 |
| 266 | EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. <i>European Urology</i> , 2011 , 59, 997-1008 | 10.2 | 557 |
| 265 | Individual learning curve reduces the clinical value of urinary cytology. 2011 , 9, 22-6 | | 11 |
| 264 | ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder. 2011 , 11, 22 | | 49 |
| 263 | Recent and potential developments in the analysis of urine: a review. 2011 , 684, 8-20 | | 133 |
| 262 | Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. 2011 , 20, 1483-91 | | 104 |
| 261 | Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria. 2011 , 87, 35-41 | | 11 |
| 260 | Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors. 2011 , 87, 134-7 | | 20 |
| 259 | Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy. 2011 , 87, 445-9 | | 5 |
| 258 | Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer. 2011 , 45, 113-21 | | 15 |
| 257 | Non-invasive urine based tests for the detection of bladder cancer. 2012 , 65, 970-5 | | 21 |
| 256 | Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis. 2012 , 19, 3653-63 | | 38 |
| 255 | Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder. 2012 , 2012, 397412 | | 19 |
| 254 | Epigenetic alterations in bladder cancer and their potential clinical implications. 2012 , 2012, 546917 | | 17 |
| 253 | Metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer. 2012 , 35, 639-42 | | 38 |
| 252 | Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. 2012 , 30, 635-45 | | 39 |
| 251 | Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential. 2012 , 12, 743-52 | | 8 |
| 250 | Evaluation of acridine orange fluorescence in exfoliative urinary cytology for diagnosing bladder carcinoma. 2012 , 44, 1375-82 | | 7 |

| | | |
|-----|--|---------|
| 249 | Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer. 2012 , 414, 93-100 | 37 |
| 248 | The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. 2012 , 30, 821-4 | 23 |
| 247 | Surveillance mēdico-professionnelle des travailleurs exposē ou ayant t' exposē ā des agents cancfogēes chimiques : application aux cancfogēes pour la vessie. Recommandations de bonne pratique. 2012 , 73, 607-633 | 3 |
| 246 | Uroepithelial and kidney carcinoma in Lynch syndrome. 2012 , 11, 395-401 | 18 |
| 245 | Bladder wash cytology at diagnosis of Ta-T1 bladder cancer is predictive for recurrence and progression. 2012 , 80, 625-31 | 1 |
| 244 | Recent advances in urinary bladder cancer detection. 2012 , 12, 929-39 | 13 |
| 243 | [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. 2012 , 36, 389-402 | 49 |
| 242 | Influencing factors on the NMP-22 urine assay: an experimental model. 2012 , 12, 23 | 39 |
| 241 | EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. 2012 , 36, 389-402 | 3 |
| 240 | Evaluation of tissue and urinary survivin expression in non-muscle-invasive bladder cancer. 2012 , 18, 143-148 | 1 |
| 239 | Detection of hyaluronidase RNA and activity in urine of schistosomal and non-schistosomal bladder cancer. 2012 , 29, 3345-51 | 14 |
| 238 | Urine-based Biomarkers. 2012 , 655-678 | |
| 237 | Urine-Based Assays Complementing Cytologic Examination in the Detection of Urothelial Neoplasm. 2012 , 109-121 | |
| 236 | Targeting bladder tumor cells in voided urine of Chinese patients with FITC-CSNRDARRC peptide ligand. 2012 , 5, 85-90 | 4 |
| 235 | [Non-muscle invasive transitional cell carcinoma of the bladder. New developments in diagnostics and therapy]. 2012 , 51, 791-7 | 0 |
| 234 | In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors. 2012 , 44, 793-8 | 7 |
| 233 | Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. <i>European Urology</i> , 2012 , 61, 185-92 | 10.2 32 |
| 232 | Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. <i>European Urology</i> , 2012 , 62, 290-302 | 10.2 84 |

| | | | |
|-----|---|------|-----|
| 231 | Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival. 2012 , 8, e42-8 | | 23 |
| 230 | A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. 2012 , 109, 941-8 | | 56 |
| 229 | EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. <i>European Urology</i> , 2013 , 64, 639-53 | 10.2 | 906 |
| 228 | Diagnostic markers of urothelial cancer based on DNA methylation analysis. 2013 , 13, 275 | | 36 |
| 227 | [Urine marker systems for diagnosis of urothelial cancer]. 2013 , 52, 965-9 | | 3 |
| 226 | Surveillance for urinary tract cancer in Lynch syndrome. 2013 , 12, 279-84 | | 15 |
| 225 | Multiplex protein signature for the detection of bladder cancer in voided urine samples. 2013 , 190, 2257-62 | | 39 |
| 224 | Republished: non-invasive urine based tests for the detection of bladder cancer. 2013 , 89, 352-7 | | 1 |
| 223 | Office-based management of nonmuscle invasive bladder cancer. 2013 , 40, 473-9 | | 4 |
| 222 | The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. 2014 , 32, 651-9 | | 17 |
| 221 | Urinmarkersysteme zur Diagnostik des Urothelkarzinoms. 2013 , 8, 24-29 | | |
| 220 | Urinary biomarkers of bladder cancer: an update and future perspectives. 2013 , 7, 779-90 | | 25 |
| 219 | Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. 2013 , 189, 1945-51 | | 37 |
| 218 | Kidney and Bladder Cancer. 2013 , 537-555 | | |
| 217 | Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis. 2013 , 11, 56-62 | | 54 |
| 216 | A review of reporting systems and terminology for urine cytology. 2013 , 121, 9-14 | | 69 |
| 215 | A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine. 2013 , 19, 4760-9 | | 49 |
| 214 | Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. 2013 , 17, 71-84 | | 94 |

| | | |
|-----|---|----|
| 213 | Urinary cytology for the detection of urothelial carcinoma of the bladder--a flawed adjunct to cystoscopy?. 2013 , 31, 366-71 | 10 |
| 212 | Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with Schistosoma haematobium infection. 2013 , 8, e59089 | 26 |
| 211 | DNA methylation-based biomarkers in bladder cancer. 2013 , 10, 327-35 | 93 |
| 210 | Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. 2013 , 133, 2631-41 | 77 |
| 209 | microRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (Review). 2013 , 30, 535-44 | 33 |
| 208 | HtrA1 in human urothelial bladder cancer: a secreted protein and a potential novel biomarker. 2013 , 133, 2650-61 | 21 |
| 207 | Alterations of DNA methylome in human bladder cancer. 2013 , 8, 1013-22 | 50 |
| 206 | Cytologic and cystoscopic predictors of recurrence and progression in patients with low-grade urothelial carcinoma. 2013 , 121, 398-402 | 8 |
| 205 | Biomarkers for detection and surveillance of bladder cancer. 2008 , 2, 212-21 | 99 |
| 204 | Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. 2014 , 12, 199 | 12 |
| 203 | What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?. 2014 , 40, 228-32 | 2 |
| 202 | Copy number aberrations using multicolour fluorescence in situ hybridization (FISH) for prognostication in non-muscle-invasive bladder cancer (NIMBC). 2014 , 113, 662-7 | 17 |
| 201 | Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis. 2014 , 446, 1047-52 | 44 |
| 200 | Urine markers for detection and surveillance of bladder cancer. 2014 , 32, 222-9 | 77 |
| 199 | Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. 2014 , 87, 715-24 | 32 |
| 198 | A novel urine cytology stain for the detection and monitoring of bladder cancer. 2014 , 192, 1628-32 | 10 |
| 197 | Assessing the quality of studies on the diagnostic accuracy of tumor markers. 2014 , 32, 1051-60 | 15 |
| 196 | Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. 2014 , 32, 1069-77 | 27 |

| | | |
|-----|--|-----|
| 195 | Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. 2014 , 51, 200-31 | 57 |
| 194 | External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. 2014 , 23, 1804-12 | 37 |
| 193 | Bladder cancer invasion predictability based on preoperative neutrophil-lymphocyte ratio. 2014 , 35, 6601-5 | 40 |
| 192 | Urine Cytopathology and Ancillary Methods. 2014 , 7, 77-88 | 10 |
| 191 | Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. 2014 , 32, 1061-8 | 30 |
| 190 | Urine tenascin-C is an independent risk factor for bladder cancer patients. 2014 , 9, 961-6 | 10 |
| 189 | Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis. 2015 , 163, 922-31 | 140 |
| 188 | The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review. 2015 , 43, 307-14 | 15 |
| 187 | New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer. 2015 , 56, 553-64 | 8 |
| 186 | Urine microRNAs as biomarkers for bladder cancer: a diagnostic meta-analysis. 2015 , 8, 2089-96 | 10 |
| 185 | New and promising strategies in the management of bladder cancer. 2015 , 105-12 | 14 |
| 184 | Combined use of epithelial membrane antigen and nuclear matrix protein 52 as sensitive biomarkers for detection of bladder cancer. 2015 , 30, e407-13 | 3 |
| 183 | Diagnostic Value of Liquid-Based Cytology in Urothelial Carcinoma Diagnosis: A Systematic Review and Meta-Analysis. 2015 , 10, e0134940 | 10 |
| 182 | Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor. 2015 , 2015, 840640 | 15 |
| 181 | Developing proteomic biomarkers for bladder cancer: towards clinical application. 2015 , 12, 317-30 | 58 |
| 180 | Bladder cancer screening in aluminum smelter workers. 2015 , 57, 421-7 | 10 |
| 179 | Noninvasive approaches for detecting and monitoring bladder cancer. 2015 , 15, 283-94 | 7 |
| 178 | [Follow-up of urothelial carcinoma: Review of the Cancer Committee of the French Association of Urology]. 2015 , 25, 616-24 | 2 |

| | | |
|-----|---|-----|
| 177 | Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. 2015 , 94, 1-24 | 114 |
| 176 | Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic. 2015 , 20, 328-37 | 6 |
| 175 | Diagnosis and staging of bladder cancer. 2015 , 29, 205-18, vii | 41 |
| 174 | Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. 2015 , 136, 854-62 | 97 |
| 173 | Genetic and Epigenetic Alterations in Bladder Cancer. 2016 , 20, S84-94 | 36 |
| 172 | Endoscopic Treatment of Bladder Tumors. 2016 , 83-203 | 0 |
| 171 | Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE). 2016 , 2, 27-36 | 51 |
| 170 | Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis. 2016 , 2016, 4591910 | 8 |
| 169 | The occult urothelial cancer. 2016 , 83, 55-60 | |
| 168 | Preoperative neutrophil-lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer. 2016 , 9, 4917-22 | 18 |
| 167 | Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations. 2016 , 34, 460-8 | 37 |
| 166 | MicroRNA expression profiling in bladder cancer: the challenge of next-generation sequencing in tissues and biofluids. 2016 , 138, 2334-45 | 47 |
| 165 | A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer. 2016 , 25, 1361-6 | 7 |
| 164 | Nested quantitative PCR approach for urinary cell-free EZH2 mRNA and its potential clinical application in bladder cancer. 2016 , 139, 1830-8 | 4 |
| 163 | Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer. 2016 , 12, 3143-3152 | 7 |
| 162 | A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer. 2016 , 2, 301-317 | 63 |
| 161 | Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. 2016 , 34, 1405-9 | 23 |
| 160 | Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. 2016 , 47, 22-31 | 53 |

| | | |
|-----|---|----|
| 159 | Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. 2016 , 16, 1189-1199 | 7 |
| 158 | Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. 2016 , 34, 437-51 | 18 |
| 157 | Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project. 2016 , 34, 452-9 | 17 |
| 156 | Methodologies for bladder cancer detection with Raman based urine cytology. 2016 , 8, 4991-5000 | 19 |
| 155 | A Comprehensive Investigation toward the Indicative Proteins of Bladder Cancer in Urine: From Surveying Cell Secretomes to Verifying Urine Proteins. 2016 , 15, 2164-77 | 11 |
| 154 | Immunocytochemical staining for p53 and Ki-67 helps to characterise urothelial cells in urine cytology. 2016 , 27, 456-464 | 8 |
| 153 | Ubiquilin2 as a novel marker for detection of urothelial carcinoma cells in urine. 2016 , 44, 3-9 | 8 |
| 152 | Ancillary Studies in Urinary Cytology. 2016 , 115-136 | 2 |
| 151 | Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria. 2016 , 195, 601-7 | 60 |
| 150 | H19 non-coding RNA in urine cells detects urothelial carcinoma: a pilot study. 2017 , 22, 661-666 | 9 |
| 149 | Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer. 2017 , 18, 381-387 | 14 |
| 148 | Non-visible asymptomatic haematuria: a review of the guidelines from the urologist's perspective. 2017 , 17, 203-216 | 1 |
| 147 | UroMark-a urinary biomarker assay for the detection of bladder cancer. 2017 , 9, 8 | 55 |
| 146 | Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics. 2017 , 23, 3700-3710 | 17 |
| 145 | Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. 2017 , 143, 1757-1769 | 8 |
| 144 | UBC Rapid Test for detection of carcinoma in situ for bladder cancer. 2017 , 39, 1010428317701624 | 21 |
| 143 | Combining Protein and miRNA Quantification for Bladder Cancer Analysis. 2017 , 9, 23420-23427 | 32 |
| 142 | Multiple functional strategies for amplifying sensitivity of amperometric immunoassay for tumor markers: A review. 2017 , 98, 100-112 | 64 |

| | | |
|-----|--|----|
| 141 | Noninvasive Diagnosis of High-Grade Urothelial Carcinoma in Urine by Raman Spectral Imaging. 2017 , 89, 6893-6899 | 31 |
| 140 | Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers. 2017 , 3, 265-272 | 33 |
| 139 | Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. 2017 , 184, 108-117 | 41 |
| 138 | Current Concepts in the Management of Non-Muscle Invasive Bladder Cancer. 2017 , 8, 397-402 | |
| 137 | Outpatient photodynamic-guided diagnosis of carcinoma in situ with flexible cystoscopy: an alternative to conventional inpatient photodynamic-guided bladder biopsies in the operating theatre?. 2017 , 51, 376-380 | 4 |
| 136 | Selection of reference genes for gene expression studies in human bladder cancer using SYBR-Green quantitative polymerase chain reaction. 2017 , 14, 6001-6011 | 8 |
| 135 | Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes. 2017 , 18, 47-59 | 18 |
| 134 | Microdevices for Non-Invasive Detection of Bladder Cancer. 2017 , 5, 30 | 7 |
| 133 | ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review. 2017 , 14, 554-559 | 2 |
| 132 | Soluble chemokine (C-X-C motif) ligand 16 (CXCL16) in urine as a novel biomarker candidate to identify high grade and muscle invasive urothelial carcinomas. 2017 , 8, 104946-104959 | 5 |
| 131 | Neutrophil-to-lymphocyte ratio is elevated in recurring nonmuscle invasive bladder cancer. 2017 , 47, 234-239 | |
| 130 | Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study. 2017 , 14, 811-819 | 33 |
| 129 | The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review. 2018 , 10, 673-687 | 20 |
| 128 | Current approaches for identifying high-risk non-muscle invasive bladder cancer. 2018 , 18, 223-235 | 5 |
| 127 | Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer. 2018 , 18, 443-455 | 6 |
| 126 | Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. 2018 , 121, 29-37 | 65 |
| 125 | The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer. 2018 , 199, 74-80 | 19 |
| 124 | Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection. 2018 , 199, 655-662 | 32 |

| | | |
|-----|--|--------|
| 123 | Urine miRNA as a potential biomarker for bladder cancer detection - a meta-analysis. 2018 , 71, 177-185 | 25 |
| 122 | Comparison of the diagnostic performance of fluorescence in situ hybridization (FISH), nuclear matrix protein 22 (NMP22), and their combination model in bladder carcinoma detection: a systematic review and meta-analysis. 2019 , 12, 349-358 | 6 |
| 121 | New Insights in Bladder Cancer Diagnosis: Urinary miRNAs and Proteins. 2018 , 6, | 10 |
| 120 | UBC Test-A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study. 2018 , 19, | 13 |
| 119 | Current Use and Promise of Urinary Markers for Urothelial Cancer. 2018 , 19, 96 | 17 |
| 118 | Urine Cytology and Urinary Biomarkers. 2018 , 67-81 | 1 |
| 117 | Surveillance for Non-Muscle-Invasive Bladder Cancer. 2018 , 541-551 | |
| 116 | Electrochemical ELISA-based platform for bladder cancer protein biomarker detection in urine. 2018 , 117, 620-627 | 30 |
| 115 | Transcriptomic analysis of high-throughput sequencing about circRNA, lncRNA and mRNA in bladder cancer. 2018 , 677, 189-197 | 34 |
| 114 | Symptoms and Diagnostic Tools for Bladder Cancer. 2018 , 1-5 | 1 |
| 113 | Application of fluorescence hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population. 2019 , 6, 114-121 | 3 |
| 112 | Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment. 2019 , 123, 246-251 | 1 |
| 111 | Symptoms and Diagnostic Tools for Bladder Cancer. 2019 , 303-307 | |
| 110 | Early-Invasive Urothelial Bladder Carcinoma and Instillation Treatment of Non-muscle-Invasive Bladder Cancer. 2019 , 327-335 | |
| 109 | Tumor M2-PK: A novel urine marker of bladder cancer. 2019 , 14, e0218737 | 6 |
| 108 | Detection of Clinical Mesenchymal Cancer Cells from Bladder Wash Urine for Real-Time Detection and Prognosis. <i>Cancers</i> , 2019 , 11, | 6.6 10 |
| 107 | TGFBI Protein Is Increased in the Urine of Patients with High-Grade Urothelial Carcinomas, and Promotes Cell Proliferation and Migration. 2019 , 20, | 4 |
| 106 | Correlation of neutrophil-lymphocyte ratio and risk scores in non-muscle invasive bladder cancer. 2019 , 43, 503-508 | 1 |

| | | | |
|-----|---|------|----|
| 105 | Off-Resonance SERS Nanoprobe-Targeted Screen of Biomarkers for Antigens Recognition of Bladder Normal and Aggressive Cancer Cells. 2019 , 91, 8213-8220 | | 18 |
| 104 | Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer. 2019 , 127, 465-469 | | 21 |
| 103 | OSblca: A Web Server for Investigating Prognostic Biomarkers of Bladder Cancer Patients. 2019 , 9, 466 | | 26 |
| 102 | Early-Invasive Urothelial Bladder Carcinoma and Instillation Treatment of Non-muscle-Invasive Bladder Cancer. 2019 , 1-9 | | |
| 101 | Plasma miRNA profile is a biomarker associated with urothelial carcinoma in chronic hemodialysis patients. 2019 , 316, F1094-F1102 | | 6 |
| 100 | Molecular Biomarkers and Urinary Bladder Cancer (UBC). 2019 , 219-235 | | |
| 99 | Recent advances in the metabolomic study of bladder cancer. 2019 , 16, 315-324 | | 16 |
| 98 | Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review. 2019 , 43, 404-413 | | 1 |
| 97 | Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review. 2019 , 43, 404-413 | | |
| 96 | Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. <i>European Urology</i> , 2019 , 75, 853-860 | 10.2 | 42 |
| 95 | Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia. 2019 , 32, 717-724 | | 21 |
| 94 | Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer. 2019 , 72, 140-144 | | 29 |
| 93 | Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. 2019 , 5, 681-688 | | 26 |
| 92 | Noninvasive Detection and Localization of Genitourinary Cancers Using Urinary Sediment DNA Methylomes and Copy Number Profiles. <i>European Urology</i> , 2020 , 77, 288-290 | 10.2 | 6 |
| 91 | Multiparameter urine analysis for quantitative bladder cancer surveillance of orthotopic xenografted mice. 2020 , 20, 634-646 | | 9 |
| 90 | Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing. 2020 , 66, 188-198 | | 15 |
| 89 | Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study. 2020 , 38, 935.e1-935.e8 | | 1 |
| 88 | Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles. <i>Cancers</i> , 2020 , 12, | 6.6 | 19 |

| | | |
|----|--|----|
| 87 | A novel diagnostic tool for the detection of bladder cancer: Measurement of urinary high mobility group box-1. 2020 , 38, 685.e11-685.e16 | 0 |
| 86 | Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. 2020 , 10, 755 | 13 |
| 85 | Bladder cancer hunting: A microfluidic paper-based analytical device. 2020 , 41, 1509-1516 | 5 |
| 84 | Design of high stability thin-film transistor biosensor for the diagnosis of bladder cancer. 2020 , 31, 1387-1391 | 12 |
| 83 | Midkine Is a Potential Urinary Biomarker for Non-Invasive Detection of Bladder Cancer with Microscopic Hematuria. 2019 , 12, 11765-11775 | 3 |
| 82 | Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer. 2020 , 128, 341-347 | 19 |
| 81 | Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial. 2020 , 38, 886-895 | 11 |
| 80 | The combination cytology/epicheck test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?. 2021 , 39, 131.e17-131.e21 | 5 |
| 79 | Advances in bladder cancer biology and therapy. 2021 , 21, 104-121 | 80 |
| 78 | Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. 2021 , 4, 93-101 | 13 |
| 77 | Adjuvant Chemotherapy in Bladder Cancer. 2021 , 251-256 | |
| 76 | Oncological Monitoring of NonMuscle Invasive Bladder Cancer (NMIBC). 2021 , 123-138 | |
| 75 | Detection of bladder cancer using voided urine sample and by targeting genomic VPAC receptors. 2021 , 37, 345-349 | 1 |
| 74 | Guideline of guidelines: Muscle-invasive bladder cancer. 2021 , 47, S71-S78 | 3 |
| 73 | Pooled analysis of Xpert Bladder Cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma. 2021 , 19, 42 | 5 |
| 72 | A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer. 2021 , 13, 91 | 11 |
| 71 | Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis. 2021 , 156, 926-933 | 2 |
| 70 | Influencing Factors on the OncuriaUrinalysis Assay: An Experimental Model. 2021 , 11, | 4 |

| | | |
|----|---|----|
| 69 | A novel electrochemical sensor based on process-formed laccase-like catalyst to degrade polyhydroquinone for tumor marker. 2021 , 235, 122736 | 0 |
| 68 | UriBLAD: A Urine-Based Gene Expression Assay for Noninvasive Detection of Bladder Cancer. 2021 , 23, 61-70 | |
| 67 | Upper Tract Urothelial Carcinoma: Ureteroscopic Biopsy and Specimen Preparation. 2015 , 1-15 | 1 |
| 66 | Genitourinary cytopathology (kidney and urinary tract). 2014 , 160, 149-83 | 15 |
| 65 | Urothelial Tumors of the Bladder. 2012 , 2309-2334.e6 | 6 |
| 64 | Correlation of neutrophil-lymphocyte ratio and risk scores in non-muscle invasive bladder cancer. 2019 , 43, 503-508 | 2 |
| 63 | Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood. 2012 , 7, e43345 | 11 |
| 62 | Filtration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer. 2015 , 10, e0131889 | 16 |
| 61 | MiR-21-5p in urinary extracellular vesicles is a novel biomarker of urothelial carcinoma. 2017 , 8, 24668-24678 | 51 |
| 60 | MicroRNAs in biofluids are novel tools for bladder cancer screening. 2017 , 8, 32370-32379 | 34 |
| 59 | The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. 2017 , 8, 58642-58653 | 30 |
| 58 | Multiphoton microscopy: applications in Urology and Andrology. 2014 , 3, 77-83 | 6 |
| 57 | Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise. 2015 , 31, 273-82 | 16 |
| 56 | Diagnostics techniques in nonmuscle invasive bladder cancer. 2015 , 31, 283-8 | 20 |
| 55 | Monitoring of the upper urinary tract in patients with bladder cancer. 2011 , 27, 238-44 | 6 |
| 54 | Is cystoscopy follow-up protocol safe for low-risk bladder cancer without muscle invasion?. 2020 , 12, 25-30 | 2 |
| 53 | Effectiveness of bladder tumor antigen quantitative test in the diagnosis of bladder carcinoma in a schistosoma endemic area. 2019 , 11, 143-148 | 5 |
| 52 | Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer. 2017 , 8, | 10 |

- 51 What is new in non-muscle-invasive bladder cancer in 2016?. **2017**, 43, 9-13 25
- 50 Urinmarker und zellbasierte Nachweisverfahren beim Urothelkarzinom. **2007**, 135-155
- 49 Evaluation of a New Urinary Bladder Tumor Marker in Comparison with Cytology for Rapid Diagnosis of Bladder TCC. **2007**, 2, 102-107
- 48 Reoperation for Bladder Cancer. **2009**, 61-79
- 47 Urothelial Bladder Cancer: Screening with Urine-Based Tumor Markers. **2010**, 196-209
- 46 Harntrakt. **2011**, 229-255
- 45 Bladder Cancer. **2012**, 325-354
- 44 Molecular Genetics and Cancer Biology. **2012**, 530-567.e16
- 43 Molecular Diagnosis of Bladder and Kidney Cancer. **2014**, 329-340
- 42 Urothelkarzinom der Harnblase: Diagnostik. **2014**, 1-14
- 41 Haematuria. **2014**, 39-47
- 40 MANAGEMENT OF CARCINOMA BLADDER: A REVIEW LITERATURE. **2014**, 4, 95-111
- 39 Low-grade Ta urothelial carcinoma of the bladder. **2015**, 104-119
- 38 Urothelkarzinom der Harnblase: Diagnostik. **2016**, 711-719
- 37 Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. **2016**, 1-43
- 36 Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. **2017**, 839-881
- 35 Urinmarker beim Blasenkarzinom. **2018**, 135-152
- 34 PET/CT in Renal, Bladder, and Testicular Cancer. **2020**, 731-754

| | | |
|----|--|-------|
| 33 | Current status of photodynamic technology for urothelial cancer. 2021 , | 3 |
| 32 | Urinmarker und zellbasierte Nachweisverfahren beim Urothelkarzinom. 2007 , 135-155 | |
| 31 | Epigenetic markers for bladder cancer in urine. 2007 , 2, 35-42 | |
| 30 | Metabolomics in bladder cancer: a systematic review. 2015 , 8, 11052-63 | 33 |
| 29 | Diagnostic value of urinary microRNAs as non-invasive biomarkers for bladder cancer: a meta-analysis. 2015 , 8, 15432-40 | 8 |
| 28 | Immunocytochemical detection of minichromosome maintenance protein 2 as a potential urinary-based marker of bladder cancer: A prospective observational study. 2020 , 36, 32-36 | 1 |
| 27 | Involvement of haptoglobin phenotypes and genotypes in non-muscle invasive bladder cancer: A possible prognostic marker for risk stratification. 2020 , 19, 351-359 | 2 |
| 26 | Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions. 2021 , 22, | 1 |
| 25 | p53 expression in repair/reactive renal tubular cells: A potential pitfall leading to a false-positive diagnosis of urine cytology. 2021 , 10, 8846 | 1 |
| 24 | Ancillary Studies in Urinary Cytology. 2022 , 193-220 | 0 |
| 23 | Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. 2022 , 1-49 | |
| 22 | Application of Mass Spectrometry Imaging in Uro-Oncology: Discovering Potential Biomarkers.. 2022 , 12, | 1 |
| 21 | [Follow-up in superficial and metastatic bladder cancer].. 2022 , | |
| 20 | Image_1.TIF. 2020 , | |
| 19 | Table_1.DOCX. 2020 , | |
| 18 | Table_2.XLSX. 2020 , | |
| 17 | Aktuelle Diagnostik bei Blasentumor, Urindiagnostik. 1 | |
| 16 | Prognostic and Therapeutic Role of CD15 and CD15s in Cancer.. <i>Cancers</i> , 2022 , 14, | 6.6 0 |

| | | | |
|----|--|-----|---|
| 15 | Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. 2022 , 1-49 | | |
| 14 | Metal-organic frameworks as a therapeutic strategy for lung diseases. | | 0 |
| 13 | Advances in Diagnosis and Therapy for Bladder Cancer. <i>Cancers</i> , 2022 , 14, 3181 | 6.6 | 2 |
| 12 | Usefulness of the Urine Methylation Test (Bladder EpiCheck [®]) in Follow-Up Patients with Non-Muscle Invasive Bladder Cancer and Cytological Diagnosis of Atypical Urothelial Cells: An Institutional Study. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3855 | 5.1 | 1 |
| 11 | A Liquid Biopsy in Bladder Cancer: The Current Landscape in Urinary Biomarkers. 2022 , 23, 8597 | | 2 |
| 10 | Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. 2022 , 975-1022 | | 0 |
| 9 | Biomarkers of Bladder Cancer: Cell-Free DNA, Epigenetic Modifications and Non-Coding RNAs. 2022 , 23, 13206 | | 1 |
| 8 | Detection of Urinary Molecular Marker Test in Urothelial Cell Carcinoma: A Review of Methods and Accuracy. 2022 , 12, 2696 | | 1 |
| 7 | Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis. | | 0 |
| 6 | Screening of neoplastic diseases by statistical analysis of urine fluorescence spectroscopic data. Application of multivariate techniques for enhancing classification. 2022 , 112598 | | 0 |
| 5 | What is the role of CellDetect [®] in detecting and monitoring bladder cancer?. 039156032211500 | | 0 |
| 4 | Preoperative De Ritis Ratio for the Evaluation of Recurrence and Progression in Non-muscle Invasive Bladder Cancer. 2023 , 22, 15-19 | | 0 |
| 3 | Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review. | | 0 |
| 2 | Urothelkarzinom der Harnblase: Diagnostik. 2022 , 1-10 | | 0 |
| 1 | Phage vs. Phage: Direct Selections of Sandwich Binding Pairs. 2023 , 15, 807 | | 0 |